	US 11,850,235 B2
	Preventative effect of mebendazole against malignancies in neurofibromatosis
Verena Staedtke, Baltimore, MD (US); and Renyuan Bai, Baltimore, MD (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US)
Filed by THE JOHNS HOPKINS UNIVERSITY, Baltimore, MD (US)
Filed on Jul. 7, 2021, as Appl. No. 17/369,763.
Prior Publication US 2023/0035885 A1, Feb. 2, 2023
Int. Cl. A61K 31/4184 (2006.01); A61K 31/635 (2006.01); A61P 35/00 (2006.01)

CPC A61K 31/4184 (2013.01) [A61K 31/635 (2013.01); A61P 35/00 (2018.01)]

20 Claims

1. A method of delaying the development of a neurofibromatosis type 1 (NF1)-related malignancy or cancer in a subject having NF1 comprising administering to the subject a therapeutically effective amount of mebendazole (MBZ), thereby delaying the development of the NF1-related malignancy or cancer.